Vanda Pharmaceuticals (NASDAQ: VNDA) revenue
Vanda Pharmaceuticals reported revenue of $216.1m for fiscal 2025, 8.7% more than in fiscal 2024 ($198.8m). Since fiscal 2016 its revenue has grown by 48.0%, an average growth of 4.5% a year.
Vanda Pharmaceuticals has grown its revenue for 2 years in a row, and its best year of the last 10 was fiscal 2021. The biggest drop was in fiscal 2023, −24.3%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $216.1m | +8.7% | −$151.2m | −70.0% |
| 2024 | $198.8m | +3.2% | −$40.7m | −20.5% |
| 2023 | $192.6m | −24.3% | −$14.0m | −7.2% |
| 2022 | $254.4m | −5.3% | $6.3m | 2.5% |
| 2021 | $268.7m | +8.3% | $42.2m | 15.7% |
| 2020 | $248.2m | +9.2% | $27.2m | 11.0% |
| 2019 | $227.2m | +17.6% | $22.8m | 10.0% |
| 2018 | $193.1m | +17.0% | $21.7m | 11.3% |
| 2017 | $165.1m | +13.1% | −$16.9m | −10.2% |
| 2016 | $146.0m | — | −$18.6m | −12.7% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Vanda Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Vanda Pharmaceuticals ranks 245th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Vanda Pharmaceuticals, 8.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 243rd | Axogen | $225.2m | 20.2% |
| 244th | IDEAYA Biosciences | $218.7m | 3,024.4% |
| 245th | Vanda Pharmaceuticals | $216.1m | 8.7% |
| 246th | Establishment Labs | $211.1m | 27.1% |
| 247th | Cytek Biosciences | $201.5m | 0.5% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Vanda Pharmaceuticals
- How much revenue did Vanda Pharmaceuticals make in fiscal 2025?
- Vanda Pharmaceuticals reported revenue of $216.1m for fiscal 2025, compared with $198.8m in fiscal 2024.
- How much has the revenue of Vanda Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $146.0m to $216.1m: 48.0% more, an average growth of 4.5% a year.
- What was the best year for revenue at Vanda Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2021, with $268.7m.
- Where does Vanda Pharmaceuticals rank in its sector by revenue?
- It ranks 245th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Vanda Pharmaceuticals come from?
- From the annual report (Form 10-K) that Vanda Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Vanda Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Vanda Pharmaceuticals: the Vanda Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.